Today: 22 January 2026
Subscribe
Browse Category

Pfizer News 22 December 2025 - 13 January 2026

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

New York, Jan 13, 2026, 15:07 EST — Regular session. Pfizer shares dipped 0.6% to $25.12 by mid-afternoon Tuesday, continuing a volatile stretch for the drugmaker as investors digested its recent comments on obesity treatments. The stock fluctuated between $24.98 and $25.42 during the session. The selling comes as CEO Albert Bourla pushes to sharpen Pfizer’s post-COVID growth narrative and…
13 January 2026
···
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

New York, Jan 13, 2026, 10:50 (EST) — Regular session Pfizer Inc (PFE) shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase…
13 January 2026
··
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

NEW YORK, Jan 3, 2026, 15:55 ET — Market closed Pfizer Inc (NYSE: PFE) shares last closed up 1.1% at $25.18 on Friday, after a weak finish to 2025. U.S. markets were closed on Saturday. The stock is starting 2026 with drug pricing back in focus, a recurring risk for big pharma that can weigh on sentiment. Drugmakers raised U.S.…
3 January 2026
····
Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 20:51 ET — Market closed Pfizer Inc (PFE) shares last traded at $24.90, down 0.4% from the previous close, with U.S. markets closed on Thursday for the New Year’s Day holiday. Reuters reported Pfizer is leading a new round of U.S. list-price increases for 2026, planning hikes on around 80 drugs and vaccines — including…
2 January 2026
····
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 06:48 ET — Market closed Pfizer Inc shares were last indicated slightly lower after hours on Wednesday after a report said the drugmaker plans to raise U.S. list prices on about 80 medicines in 2026. U.S. stock markets were closed on Thursday for the New Year’s Day holiday. (Reuters) Why it matters now: January is…
1 January 2026
····
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

NEW YORK, December 31, 2025, 18:50 ET — After-hours Pfizer Inc. shares fell about 0.4% to $24.90 in after-hours trading on Wednesday, after a report said the drugmaker is leading a wave of U.S. list-price increases set for 2026. The data, compiled by healthcare research firm 3 Axis Advisors, showed drugmakers plan hikes on at least 350 branded medicines, with…
1 January 2026
····
Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

NEW YORK, December 31, 2025, 14:53 ET — Regular session Pfizer shares were down 0.1% at $24.96 in afternoon trade on Wednesday after a Reuters report said the drugmaker plans U.S. list-price hikes on about 80 medicines in 2026. Reuters The planned increases, set to start Jan. 1, land at a sensitive moment for drug pricing as the Trump administration…
31 December 2025
····
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

NEW YORK, December 30, 2025, 13:50 ET — Regular session Pfizer Inc (NYSE:PFE) shares were up about 0.1% at $25.03 in afternoon trading on Tuesday, after moving between $24.92 and $25.10. TD Cowen reiterated its Hold rating and kept a $30 price target, pointing to negative trends in its model through 2030 despite the stock’s dividend yield near 7%. Investing…
30 December 2025
····
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer Inc. (NYSE: PFE) stock is spending Christmas Eve in the familiar “mid-$20s” zone — a level that has become a psychological battleground for investors trying to decide whether Pfizer is a high-yield value play, a turnaround story, or simply a “show-me” stock until growth returns. As of Dec. 24, 2025, Pfizer shares were trading around $25 in holiday-thinned markets,…
24 December 2025
····
Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (NYSE: PFE) ended Tuesday’s session (December 23, 2025) lower, then steadied in extended trading as investors digested a late-day safety headline tied to its hemophilia medicine Hympavzi (marstacimab). After-hours snapshot (as of 6:56 p.m. ET): PFE traded around $24.92, up about 0.16% in after-hours action, after closing the regular session at $24.88. Yahoo FinanceDuring Tuesday’s regular session, PFE ranged…
24 December 2025
····
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Dec. 23, 2025 — Pfizer Inc. (NYSE: PFE) stock is ending 2025 in a familiar tug-of-war: a high-yield “value” profile on the one hand, and lingering uncertainty about the company’s post‑COVID growth engine on the other. Shares were trading around $25.15 on Tuesday, keeping the stock in the mid‑$20s range that’s defined much of its recent tape. Today’s news flow…
23 December 2025
····
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

As of Monday, December 22, 2025, Pfizer (NYSE: PFE) is once again at the center of a familiar market debate: is this a battered pharma giant destined to stay “dead money,” or a dividend-rich turnaround story that could surprise investors as its pipeline matures? The short-term reality is tough to miss. Pfizer has guided to flat-to-down revenue in 2026, with…
22 December 2025
····
1 2

Stock Market Today

  • Meta Platforms Stock Price Forecast 2026: AI Focus Drives Outlook Amid Metaverse Losses
    January 22, 2026, 9:26 AM EST. Meta Platforms (NASDAQ: META) faces a mixed outlook as it shifts from costly metaverse investments in its Reality Labs division toward artificial intelligence (AI) integration across Facebook, Instagram, Messenger, and WhatsApp. Despite Reality Labs reporting a $4.43 billion operational loss in Q3 2025, Meta's overall revenue rose 26% year-over-year to $51.2 billion, surpassing analyst expectations. CEO Mark Zuckerberg's pivot to AI aims to enhance user engagement and establish a competitive moat. The stock, down 18% since its Q3 earnings report and underperforming the broader market with a 3.6% rise year-over-year, remains influenced by economic uncertainties and investor concerns. Continued strong earnings and AI-driven growth will be key factors as investors monitor Meta's trajectory into 2026.
Go toTop